Human IgG2 Can Form Covalent Dimers1

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of Immunology

• Publication date

  2003-03-15

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.4049/jimmunol.170.6.3134PMID 12626570
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A human immunoglobulinIGHG3 allele (Gmb0, b1, c3, c5, u) with anIGHG4 converted region and three hinge exons

  2006cited by this paper
• Basic and clinical immunology.

  2005cited by this paper
• Antigenic similarities of rat and mouse IgG subclasses associated with anti-carbohydrate specificities

  2005cited by this paper
• Detection of immunoglobulin heavy chain IgG3 polymorphism in wild mice with xenogeneic monoclonal antibodies

  2004cited by this paper
• Deficient IgA and IgG2 anti-pneumococcal antibody levels and response to vaccination in otitis prone children.

  2002cited by this paper
• The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds.

  2001cited by this paper
• A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity.

  1999cited by this paper
• The Apparent Monovalency of Human IgG4 Is Due to Bispecificity

  1999influential reference
• Immunoglobulin deficiencies and impaired immune response to polysaccharide antigens in adult patients with recurrent community-acquired pneumonia.

  1997cited by this paper
• Intrachain disulfide bond in the core hinge region of human IgG4

  1997influential reference
• The IGHG3 gene shows a structural polymorphism characterized by different hinge lengths: sequence of a new 2-exon hinge gene

  1996cited by this paper
• Reactive disulfide bonds in immunoglobulin G. A unique feature in serum proteins of different species

  1996cited by this paper
• Variable region-identical monoclonal antibodies of different IgG subclass directed to Pseudomonas aeruginosa lipopolysaccharide O-specific side chain function differently.

  1993influential reference
• A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody.

  1993cited by this paper
• Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. 1979.

  1992cited by this paper
• IgG subclass deficiencies and recurrent pyogenic infections, unresponsiveness against bacterial polysaccharide antigens.

  1992cited by this paper
• Expression, purification and characterization of a mouse-human chimeric antibody and chimeric Fab' fragment.

  1992cited by this paper
• IgG subclass deficiencies and recurrent pyogenic infections, unresponsiveness against bacterial polysaccharide antigens.

  1992cited by this paper
• The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region

  1991cited by this paper
• H chain C domains influence the strength of binding of IgG for streptococcal group A carbohydrate.

  1991cited by this paper
• Impaired polysaccharide responses in immunodeficient patients: relevance to bone marrow transplant patients.

  1991cited by this paper
• Influence of the hinge region on complement activation, C1q binding, and segmental flexibility in chimeric human immunoglobulins.

  1990cited by this paper
• A view of the human idiotypic repertoire. Electron microscopic and immunologic analyses of spontaneous idiotype-anti-idiotype dimers in pooled human IgG.

  1990cited by this paper
• Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3.

  1989cited by this paper
• IgG3 is the major source of cryoglobulins in mice.

  1989cited by this paper
• Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region.

  1989cited by this paper
• Sequence of a rat immunoglobulin y2c heavy chain constant region cDNA: extensive homology to mouse y3

  1988cited by this paper
• Sequence of a rat immunoglobulin gamma 2c heavy chain constant region cDNA: extensive homology to mouse gamma 3.

  1988cited by this paper
• Purification of murine IgG3 and IgM monoclonal antibodies by euglobulin precipitation.

  1988cited by this paper
• Immunoglobulin G dimer: an idiotype-anti-idiotype complex.

  1988cited by this paper
• Interaction of IgG3 anti-streptococcal group A carbohydrate (GAC) antibody with streptococcal group A vaccine: enhancing and inhibiting effects of anti-GAC, anti-isotypic, and anti-idiotypic antibodies.

  1987cited by this paper
• Sequence of a human immunoglobulin gamma 3 heavy chain constant region gene: comparison with the other human C gamma genes.

  1986cited by this paper
• Polymorphism of heavy chain immunoglobulin isotypes in the Mus subgenus

  1984cited by this paper
• Subclass restriction of murine antibodies. V. The IgG plaque-forming cell response to thymus-independent and thymus-dependent antigens in athymic and euthymic mice.

  1982cited by this paper
• Linkage and sequence homology of two human immunoglobulin gamma heavy chain constant region genes.

  1982cited by this paper
• The primary structure of a human IgG2 heavy chain: genetic, evolutionary, and functional implications.

  1980cited by this paper
• Subclass restriction of murine antibodies. III. Antigens that stimulate IgG3 in mice stimulate IgG2c in rats

  1980cited by this paper
• Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

  1979cited by this paper
• Subclass restriction of murine anti-carbohydrate antibodies.

  1978influential reference
• REVIEW OF THE NOTATION FOR THE ALLOTYPIC AND RELATED MARKERS OF HUMAN IMMUNOGLOBULINS

  1976cited by this paper
• Natural Infection of Man with Group A Streptococci

  1976cited by this paper
• Basic and Clinical Immunology

  1976cited by this paper
• IMMUNOCHEMICAL STUDIES ON MOUSE MYELOMA PROTEINS REACTIVE WITH DEXTRANS OR WITH FRUCTOSANS AND ON HUMAN ANTILEVANS

  1974cited by this paper
• Three classes and four (sub)classes of rat immunoglobulins: IgM, IgA, Ige and IgG1, IgG2a, IgG2b, IgG2c

  1974cited by this paper
• Structural Studies of Immunoglobulins

  1973cited by this paper
• Genetics of the Antibody Response to Dextran in Mice

  1972cited by this paper
• Antigenic determinants on immunoglobulins of nonhuman primates.

  1972cited by this paper
• Antigenic determinants on immunoglobulins of nonhuman primates.

  1972cited by this paper
• Antigen-binding myeloma proteins in mice.

  1971cited by this paper
• ANTIGEN‐BINDING MYELOMA PROTEINS IN MICE

  1971cited by this paper
• Disulphide bridges of the heavy chain of human immunoglobulin G2.

  1971cited by this paper
• A NEW MOUSE IMMUNOGLOBULIN: IGG3

  1971cited by this paper
• Immunochemical studies of the reaction between a mouse myeloma macroglobulin and dextrans.

  1970cited by this paper
• Immunoglobulins: Structural Studies of Immunoglobulin G

  1969cited by this paper
• Structural studies of immunoglobulin G.

  1969cited by this paper
• STUDIES ON HUMAN ANTIBODIES

  1968cited by this paper
• STUDIES ON HUMAN ANTIBODIES

  1965cited by this paper
• Immunochemical studies on cross-reactions of antipneumococcal sera-V. Cross-reactions of horse antipneumococcal type II serum with E. coli M-II polysaccharide, dextran and hemocyanin-ortho-azophenyl-beta-glucuronide.

  1960influential reference

• Polyclonal Antibody Therapeutics: Analytical Innovations and Regulatory Perspectives for Addressing Heterogeneity Challenges.

  2026cites this paper
• An asymmetric tetrabody is a potent and efficacious agonist of the erythropoietin receptor in vitro and in vivo

  2025cites this paper
• Research progress of antibody coupling technique in targeted drug delivery

  2025cites this paper
• Targeted drug conjugates in cancer therapy: Challenges and opportunities

  2024cites this paper
• Translating mechanisms into therapeutic strategies for immune thrombocytopenia (ITP): Lessons from clinical trials.

  2024cites this paper
• Proximity-inducing modalities: the past, present, and future.

  2023cites this paper
• Shared and Unique Antibody and B cell Profiles in HIV-Positive and HIV-Negative Individuals with Cryptococcal Meningoencephalitis.

  2023cites this paper
• Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologist’s Perspective

  2021cites this paper
• Antibody–Drug Conjugates—A Tutorial Review

  2021cites this paper
• Novel therapies for immune thrombocytopenia

  2021cites this paper
• Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo

  2021cites this paper
• The Best IgG Subclass for the Development of Therapeutic Monoclonal Antibody Drugs and their Commercial Production: A Review

  2020cites this paper
• Optimizing TNFR2 antagonism for immunotherapy with tumor microenvironment specificity

  2020cites this paper
• Engineering a human IgG2 antibody stable at low pH

  2020cites this paper
• Cysteine in cell culture media induces acidic IgG1 species by disrupting the disulfide bond network

  2020cites this paper
• The Role of IgG Subclass in Antibody-Mediated Protection against Carbapenem-Resistant Klebsiella pneumoniae

  2020cites this paper
• Next generation of anti-PD-L1 Atezolizumab with better anti-tumor efficacy in vivo

  2020cites this paper
• Engineering the Human Fc Region Enables Direct Cell Killing by Cancer Glycan–Targeting Antibodies without the Need for Immune Effector Cells or Complement

  2020cites this paper
• Modifications of recombinant monoclonal antibodies in vivo.

  2019cites this paper
• The solution structure of the human IgG2 subclass is distinct from those for human IgG1 and IgG4 providing an explanation for their discrete functions

  2019cites this paper
• Antibody-mediated control of HIV-1 infection through an alternative pathway.

  2019cites this paper
• Susceptibility of protein therapeutics to spontaneous chemical modifications by oxidation, cyclization, and elimination reactions

  2019cites this paper
• Understanding the in vivo fate of radioimmunoconjugates for nuclear imaging.

  2018cites this paper
• Factors Affecting the Pharmacology of Antibody–Drug Conjugates

  2018cites this paper
• Engineering Antibodies for the Treatment of Infectious Diseases

  2018cites this paper
• Antibody–drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes

  2018cites this paper
• Human Fc receptor‐like 5 distinguishes IgG2 disulfide isoforms and deamidated charge variants

  2017cites this paper
• IgG cooperativity – Is there allostery? Implications for antibody functions and therapeutic antibody development

  2017cites this paper
• A fully recombinant human IgG1 Fc multimer (GL-2045) inhibits complement-mediated cytotoxicity and induces iC3b.

  2017cites this paper
• Production of IgG antibodies to pneumococcal polysaccharides is associated with expansion of ICOS+ circulating memory T follicular-helper cells which is impaired by HIV infection

  2017cites this paper
• Multimerization is required for antigen binding activity of an engineered IgM/IgG chimeric antibody recognizing a skin-related antigen

  2017cites this paper
• Assessment of disulfide and hinge modifications in monoclonal antibodies

  2017cites this paper
• Bococizumab for the treatment of hypercholesterolaemia

  2017cites this paper
• Bococizumab for the treatment of hypercholesterolaemia

  2017cites this paper
• Recent Advances in Antibody-Drug Conjugates for Breast Cancer Treatment.

  2017cites this paper
• Chemically generated IgG2 bispecific antibodies through disulfide bridging.

  2017cites this paper
• Antiviral Functions of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific IgG Antibodies: Effects of Antiretroviral Therapy and Implications for Therapeutic HIV-1 Vaccine Design

  2017cites this paper
• Characterization of Therapeutic Proteins

  2016cites this paper
• Control of early HIV-1 infection associates with plasmacytoid dendritic cell-reactive opsonophagocytic IgG antibodies to HIV-1 p24

  2016cites this paper
• Isotype switching: Mouse IgG3 constant region drives increased affinity for polysaccharide antigens

  2016cites this paper
• Anti-CD20 Antibody with Multimerized Fc Domains: A Novel Strategy To Deplete B Cells and Augment Treatment of Autoimmune Disease

  2016cites this paper
• Antibody–drug conjugates as novel anti-cancer chemotherapeutics

  2015cites this paper
• Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies

  2015cites this paper
• On the Dark Side of Therapies with Immunoglobulin Concentrates: The Adverse Events

  2015cites this paper
• Fc fusion as a platform technology: potential for modulating immunogenicity.

  2015cites this paper
• B‐1 lymphocytes in mice and nonhuman primates

  2015cites this paper
• Viremic HIV Controllers Exhibit High Plasmacytoid Dendritic Cell–Reactive Opsonophagocytic IgG Antibody Responses against HIV-1 p24 Associated with Greater Antibody Isotype Diversification

  2015cites this paper
• Effect of Hydrolytic Degradation on the In Vivo Properties of Monoclonal Antibodies

  2015cites this paper
• Oxidation of Proteins in the In Vivo Environment: What We Know; What We Need to Study and Potential Mitigation Strategies

  2015cites this paper
• Structural characterization of antibodies against lipopolysaccharide antigens: Insights into primary antibody response

  2015cites this paper
• Novel Generation of Antibody-Based Therapeutics

  2015cites this paper
• Antibody recognition of carbohydrate epitopes†.

  2015cites this paper
• Identification of Reduction-Susceptible Disulfide Bonds in Transferrin by Differential Alkylation Using O16/O18 Labeled Iodoacetic Acid

  2015cites this paper
• Assessment of naturally occurring covalent and total dimer levels in human IgG1 and IgG2.

  2014cites this paper
• Human IgG Subclasses

  2014cites this paper
• Dissecting the antibody constant region protective immune parameters in HIV infection

  2014cites this paper
• IgG Subclasses and Allotypes: From Structure to Effector Functions

  2014cites this paper
• Post-translational structural modifications of immunoglobulin G and their effect on biological activity

  2014cites this paper
• An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.

  2014cites this paper
• Antagonist properties of monoclonal antibodies targeting human CD28

  2013cites this paper
• Isotype Diversification of IgG Antibodies to HIV Gag Proteins as a Therapeutic Vaccination Strategy for HIV Infection

  2013cites this paper
• Isotype-switched immunoglobulin G antibodies to HIV Gag proteins may provide alternative or additional immune responses to ‘protective’ human leukocyte antigen-B alleles in HIV controllers

  2013cites this paper
• Comprehensive characterization of protein structures by liquid chromatography coupled with mass spectrometry (LC-MS)

  2013cites this paper
• Molecular Variants Characterization in Protein Therapeutics Development

  2013cites this paper
• Human Fc Receptor–Like 5 Binds Intact IgG via Mechanisms Distinct from Those of Fc Receptors

  2013cites this paper
• Investigating monoclonal antibody aggregation using a combination of H/DX-MS and other biophysical measurements.

  2013cites this paper
• Comparability analysis of anti-CD20 commercial (rituximab) and RNAi-mediated fucosylated antibodies by two LC-MS approaches

  2013influential citation
• Fc-Fc interactions of human IgG4 require dissociation of heavy chains and are formed predominantly by the intra-chain hinge isomer.

  2013cites this paper
• Effects of subclass change on the structural stability of chimeric, humanized, and human antibodies under thermal stress

  2013cites this paper
• Disulfide bond structures of IgG molecules

  2012cites this paper
• Antibody C Region Influences TGN1412-like Functional Activity In Vitro

  2012cites this paper
• Development of Antibody-Based Therapeutics

  2012cites this paper
• Relative stabilities of IgG1 and IgG4 Fab domains: Influence of the light–heavy interchain disulfide bond architecture

  2012cites this paper
• Fully recombinant IgG2a Fc multimers (stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenic purpura in mice

  2012cites this paper
• Quality attributes of recombinant therapeutic proteins: An assessment of impact on safety and efficacy as part of a quality by design development approach

  2012cites this paper
• Application of Antibody Engineering in the Development of Next Generation Antibody-Based Therapeutics

  2012cites this paper
• Use of a human recombinant immunoglobulin G1 CH3 domain as a probe for detecting alternatively folded human IgG in intravenous Ig products.

  2012cites this paper
• A dimerized single-chain variable fragment system for the assessment of neutralizing activity of phage display-selected antibody fragments specific for cytomegalovirus.

  2012cites this paper
• Structural biology of IgG Fc glycoforms

  2012cites this paper
• Polymeric human Fc-fusion proteins with modified effector functions

  2011cites this paper
• Antibody-drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells.

  2011cites this paper
• Isotype Selection and Fc Engineering: Design and Construction of Fit-for-Purpose Therapeutic Antibodies

  2011cites this paper
• The in vitro resistance of IgG2 to proteolytic attack concurs with a comparative paucity of autoantibodies against peptide analogs of the IgG2 hinge

  2011cites this paper
• Production of a PEGylated Fab' of the anti-LINGO-1 Li33 antibody and assessment of its biochemical and functional properties in vitro and in a rat model of remyelination.

  2011cites this paper
• Unusual increased beta-globulins in an elderly patient.

  2011cites this paper
• Acquired Humoral Immunity to Cryptococcus neoformans

  2011cites this paper
• Do regulatory antibodies offer an alternative mechanism to explain the hygiene hypothesis?

  2011cites this paper
• Disulfide Scrambling in IgG2 Monoclonal Antibodies: Insights from Molecular Dynamics Simulations

  2011cites this paper
• Focus on composition and interaction potential of single‐pass transmembrane domains

  2010cites this paper
• Characterization of antibody aggregation: role of buried, unpaired cysteines in particle formation.

  2010cites this paper
• Why antibodies disobey the Hippocratic Oath and end up doing harm: a new clue.

  2010cites this paper
• Therapeutic antibodies in HIV treatment--classical approaches to novel advances.

  2010cites this paper
• Mass Spectrometric Analysis of Intact Human Monoclonal Antibody Aggregates Fractionated by Size-Exclusion Chromatography

  2010cites this paper
• Role of ErbB2 and ErbB4 in Cancer Growth, Prognosis and as Targets for Immunotherapy

  2010cites this paper
• Stability of IgG isotypes in serum

  2010cites this paper
• Antibody–Cytotoxic Compound Conjugates for Oncology

  2010cites this paper
• Aspects of Isotype Selection

  2010cites this paper
• Vaccine-induced IgG2 anti-HIV p24 is associated with control of HIV in patients with a ‘high-affinity’ FcγRIIa genotype

  2010cites this paper
• Interactions between immunoglobulin G molecules.

  2010cites this paper
• A Multi-DNA Preventive Vaccine for p53/Neu-Driven Cancer Syndrome

  2009cites this paper